Image Credit: Credit: Susanna Hamilton
Scientific Frontline: Extended "At a Glance" Summary: Hypoxia-in-a-Pill Therapy
The Core Concept: A two-drug combination therapy designed to artificially reduce tissue oxygen levels, mimicking the therapeutic benefits of a low-oxygen environment (hypoxia) without the risks associated with continuously breathing oxygen-depleted air.
Key Distinction/Mechanism: Unlike placing subjects in physically hypoxic environments, which can lead to adverse cardiac side effects, this oral regimen utilizes the small molecule GBT601 to bind to red blood cell hemoglobin to prevent oxygen delivery, while PT2399 inhibits the HIF-2α pathway to block the body's compensatory overproduction of red blood cells.
Origin/History: First established in 2024 as a proof-of-concept by Vamsi Mootha's team at the Broad Institute, the regimen was refined into a highly effective second-generation version and published in the Proceedings of the National Academy of Sciences in October 2026.
Major Frameworks/Components:
- GBT601: A targeted molecule that increases hemoglobin's affinity for oxygen, safely restricting its release into cellular tissues.
- PT2399: An inhibitor drug targeting the HIF-2α pathway, preventing secondary compensatory responses such as the dangerous overproduction of red blood cells.
- Mitochondrial Dysfunction: The underlying cellular pathology targeted by the treatment, where malfunctioning mitochondria fail to consume oxygen properly, resulting in toxic oxygen accumulation and cellular damage.
Branch of Science: Neurology, Pharmacology, Systems Biology
Future Application: Further pre-clinical development and eventual human clinical trials for treating neurodegenerative conditions and rare mitochondrial disorders, including Parkinson's disease, Leigh syndrome, and Friedreich's ataxia.
Why It Matters: By safely inducing controlled hypoxia pharmacologically, this regimen significantly extended the lifespan of mouse models with Leigh syndrome and reversed or halted neurodegenerative symptoms in Parkinson's disease and Friedreich's ataxia, offering a highly practical therapeutic alternative for debilitating neurological conditions.
In a new paper, Broad Institute researchers report that two small-molecule chemicals that reduce oxygen delivery to cells improved symptoms of neurodegeneration in a mouse model of Parkinson’s disease. The scientists had previously found that excess oxygen in the brain is associated with neuronal death in Parkinson’s—and that reducing the oxygen that mice breathe could help reverse symptoms.
The new study, published in PNAS, also revealed that the two-drug combination extended lifespan and alleviated symptoms in a mouse model of Leigh syndrome, and helped to delay the progression of neurological symptoms in a mouse model of Friedreich's ataxia. Leigh syndrome and Friedreich’s ataxia are rare genetic disorders that occur when mitochondria, which generate energy in the cell, malfunction, often leading to high levels of unused oxygen that can damage tissues. Vamsi Mootha, an institute member at the Broad Institute who led the new study, has found over the last decade that exposure to low-oxygen conditions improved symptoms in mouse models of these two rare diseases, which in humans affect the nervous system, are debilitating, and can be fatal.
Mootha and his team say that the new drug regimen merits further preclinical and eventually clinical testing as a potential treatment for Parkinson’s disease and some mitochondrial disorders.
“Mitochondrial dysfunction is associated with many different conditions, ranging from rare diseases to universal, age-related diseases,” said Mootha, who is also a professor of systems biology and medicine at Harvard Medical School, a Howard Hughes Medical Institute investigator in the Department of Molecular Biology at Massachusetts General Hospital (MGH), and a founding member of the Mass General Brigham healthcare system. “These results are promising and offer a pharmacologically tractable form of hypoxia therapy.”
Low-Oxygen Effects
In 2024, Mootha and his team were the first to establish a proof-of-concept “hypoxia in a pill” that included two drugs. The first drug, called GBT440, targets hemoglobin, which is found in red blood cells and carries oxygen from the lungs to tissues. GBT440 binds to hemoglobin and increases its affinity for oxygen, preventing it from delivering oxygen to tissues.
The body tries to compensate for this by boosting red blood cell production, so the second drug, PT2399, blocks this response by inhibiting the HIF-2α pathway. The team reported positive effects of the experimental regimen for mitochondrial disease, but it still fell shy of achieving the benefits observed when mouse models were exposed to 11% oxygen, which is about the equivalent of breathing air at an altitude of 15,000 feet.
In the new paper, Mootha, lead author Hong Wang, a research scientist in Mootha’s lab, and their collaborators describe an optimized version of the original combination that is more effective.
This version still includes PT2399, but it replaces GBT440 with a second-generation molecule, GBT601, that is stronger and lasts longer in the body. Both belong to drug classes that are FDA-approved for other uses and have been shown to be tolerated in safety studies in healthy human volunteers.
The team gave the two drugs to 50-day-old mice with advanced Leigh syndrome and found that it extended their expected lifespan from about 62 days to 158 days, a significant jump.
In the Parkinson’s disease model, the hypoxia pill reversed movement-related symptoms in advanced disease and worked comparably to breathing 11% oxygen.
“Anecdotally, some patients with Parkinson's disease report an improvement in their symptoms at high altitude,” Mootha said. “We're excited by the prospects of a hypoxia pill that may benefit Parkinson's patients.”
In a mouse model of Friedreich’s ataxia, the researchers found that the drug combination halted further progression of the disease but did not go as far as reversing symptoms. The findings build on previous work from Mootha’s lab showing that hypoxia restores balance and coordination in the mouse model.
Long-term exposure to hypoxia can lead to pulmonary hypertension and right-sided heart failure. The team found that the drug regimen was well tolerated in the mice for over three weeks of daily treatment, and the animals did not show cardiac side effects often associated with chronic hypoxia.
Mootha emphasized that these are preclinical mouse studies and more work is needed before the findings can be directly translated into treatments. He added that chronic hypoxia can be dangerous if not delivered in a controlled clinical setting. However, he noted that the hypoxia pill is promising and should be tested further for potential clinical benefits.
Funding: This work was supported by the National Institutes of Health (grants R01NS112373, R01NS124679), the Marriott Family Foundation, the Abby Mac Foundation, the Daniel Garland Fund, and Friedreich’s Ataxia Research Alliance.
Published in journal: Proceedings of the National Academy of Sciences
Authors: Hong Wang, Eizo Marutani, Luca Zazzeron, Marissa Menard, Laura Volpicelli-Daley, Fumito Ichinose, and Vamsi K. Mootha
Source/Credit: Broad Institute | Jessica Colarossi
Edited by: Scientific Frontline
Reference Number: bio101126_01
